STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen

(Length of Discussion: 12 min)

Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial that was released at ESMO 2018. Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at effects of abiraterone acetate plus prednisone in both high and low metastatic hormone sensitive prostate cancer. Silke articulates the clinical design and data outcomes of each trial, summarizing the potential clinical application.


Silke Gillessen, MD, Professor and Chair in Genitourinary Oncology Systemic Therapy Research at The University of Manchester and The Christie NHS Foundation Trust, Co-founder of the Advanced Prostate Cancer Consensus Conference (APCCC)

Alicia Morgans, MD, MPH